PIAM, the first company on the Italian market to work in the field of hereditary metabolic diseases, has introduced innovative and technologically advanced products, devoting itself to the development of increasingly effective, practical and highly palatable formulas with a view to improve treatment compliance.
PIAM works alongside Kyowa Hakko Bio, a world leader in biotechnology and chemical synthesis, with lines of amino acids, vitamins, nucleic acids and compounds for pharmaceutical and nutritional treatments.
PIAM is a long-standing partner of Vitaflo, a company that is specialized in human nutrition for the treatment of hereditary metabolic diseases and is part of the Nestlé Health Science group.
PIAM acts as a one-stop reference point on the market, with skills in the pharmaceutical and medical food areas, offering twofold expertise with a high degree of specialisation and diverse therapeutic treatments, customised for the management of rare and niche disorders.
PIAM’s commitment never stops and it focuses on investing in research and innovation in the orphan drugs sector, a strategic market that still requires a great deal of hard work because many rare diseases are lacking in accessible and adequate treatments.
PIAM continues to work alongside the scientific community and patients, constantly seeking out the best therapeutic solutions to protect the health of all patients.
PIAM (Prodotti Igienici Alimentari Medicinali)
is founded in Genoa
Nicozid and Etapiam are launched on the market. PIAM establishes itself as market leader in the treatment of tuberculosis
PIAM is the first pharmaceutical company to import medical food in Italy for treating hereditary metabolic diseases
Change of ownership.
New shareholders and majority stake, new management and a new strategic drive
PIAM (Prodotti Igienici Alimentari Medicinali) is founded in Genoa
Nicozid and Etapiam are launched on the market. PIAM establishes itself as market leader in the treatment of tuberculosis
PIAM is the first pharmaceutical company to import medical food in Italy for treating hereditary metabolic diseases
Change of ownership.
New shareholders and majority stake, new management and a new strategic drive
2019 turnover in million €
10% CAGR 2014-2019
CMO
(Contract Manufactor Organization)
including 5 international CMOs
Presence
in Italian Hospital
Metabolic Centres
Partnerships with
Parkinson’s disease
treatment Centres
Projects underway
with Scientific
and Patient Associations
Read also
